Irinotecan as second-line treatment in metastatic colorectal cancer: Dilemmas regarding patient selection and toxicity prediction

Journal of Chemotherapy

Volumn 12, Issue 3, 2000, Pages 244-251

  Nikolic Tomasevic, Z ^a   Jelic, Svetislav ^a,b   Popov, I ^a   Radosavljevic, D ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b Institut za Onkologiju i Radiologiju   (Yugoslavia)

Author keywords

Colorectal cancer; Hepatotoxicity; Irinotecan; Nephrotoxicity

Indexed keywords

BILIRUBIN; CREATININE; IRINOTECAN; UREA; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; PLASMA PROTEIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; DIARRHEA; DRUG COST; DRUG EFFICACY; FEMALE; HEART ARRHYTHMIA; HUMAN; LIVER DYSFUNCTION; LIVER TOXICITY; LYMPHOPROLIFERATIVE DISEASE; MALE; METASTASIS; NEPHROTOXICITY; NEUTROPENIA; PARALYTIC ILEUS; PATIENT SELECTION; PNEUMONIA; TOXICITY; BLOOD; CASE REPORT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COLORECTAL TUMOR; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK FACTOR;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD PROTEINS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; CREATININE; DIARRHEA; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; PATIENT SELECTION; RISK FACTORS; UREA;

EID: 0034200464     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2000.12.3.244     Document Type: Article

References (20)

1. 1 Rothenberg ML, Hainsworth JD, Rosen L, et al. Phase II study of irinotecan (CPT-11) 250 mg/m given every-other-week in previously treated colorectal cancer patients. Proc Ann Soc Clin Oncol 1998; 17: 284a, (abstr. 1092).
2. 2 Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: 709-715.
3. 3 Rougier P, Bugar R, Doullard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251-260.
4. 4 Pitot HC, Wendr DB, O Connell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 15: 2910-2919.
5. 5 Rothenberg ML, Echardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14: 1128-1135.
6. 6 Rothenberg ML. Efficacy and toxicity of irinotecan inpatients with colorectal cancer. Semin Oncol 1998; 25 (suppl.11): 39-46.
7. 7 Abigerges D, Arnmand JP, Chabot CG, et al. Irinotecan (CPT-11) high dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994; 86: 446-449.
8. 8 Berg D. Managing the side effects of chemotherapy for colorectal cancer. Semin Oncol 1998; 25 (suppl 11): 53-59.
9. th Conference on DNA topoisomerases in therapy, Amsterdam 1995: 6-8/9/(abstr. 74).
10. 10 Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivate of camtothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10 (8): 1225-1229.
11. 11 Douillard JY, Ibrahim N, Riviere A, et al. Phase II study of CPT-11 (irinotecan) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1995; 14, 365 (abstr. 1118).
12. 12 Nakagawa K, Fukuoka M, Niitani H. Phase II study of irinotecan (CPT-11) and cisplatin in patients with advanced non-small cell lung cancer (NSCL). Proc Am Soc Clin Oncol 1993; 12, (abstr. 1104).
13. 13 Goto K, Nishiwaki Y, Saijo N, et al. A phase II study of irinotecan (CPT-11) and etoposide (VP-16) for metastatic non-small cell lung cancer (NSCLC): Japanese Clinical Oncology Group (JCOG) trial. Proc Am Soc Clin Oncol 1995; 14, 362, (abstr. 1108).
14. 14 Boisseau M, Bugat R, Mahjoubi M. Rapid tumor lysis syndrome in a metastatic colorectal cancer increased by treatment with irinotecan (CPT-11). Eur J Cancer 1996; 32A (4): 737-738.
15. 15 Milles AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
16. 16 Sikora K, Advani S, Koroltchouk V, et al. Essential drugs for cancer therapy: A World Health Organization consultation. Ann Oncol 1999; 10, 4: 385-390.
17. 17 Benson AB III. Therapy for advanced colorectal cancer. Semin Oncol 1998; 25 (suppl. 11): 2-11.
18. 18 Van Cutsem E, Cunningham D, Ten Bokkel Huinink W, et al. CPT-11 in 5-FU-resistant colorectal cancer (CRC): Patient benefit. Presented at the European Society for Medical Oncology Congress, November 1-5, 1996, Vienna, Austria.
19. 19 Van Hoff DD, Rothenberg ML, Pilot HC, et al. Irinotecan therapy for patients with previously treated metastatic colorectal cancer; Overall results of FDA-reviewed pivotal US clinical trials. Proc Am Soc Clin Oncol 1997; 16: 228, (abstr. 803).
20. st century. Published by Rhône-Poulenc Rorer, Sept. 1995.